ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ELAFIBRANOR WITH INDOMETHACIN IN HEALTHY ADULT MALE PARTICIPANTS: AN OPEN-LABEL PHASE I TRIAL

被引：0
|
作者：
Pedret-Dunn, Anna
Mazain, Sarah
Allan, Richard
Gattolliat, Olivier
Hanf, Remy
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1591
引用
收藏
页码：S1705 / S1706
页数：2
相关论文
共 50 条
  • [21] A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
    Li Chen
    Jiayi Zhang
    Yu Sun
    Yu Zhao
    Xiang Liu
    Zhiyin Fang
    Lingge Feng
    Bin He
    Quanfei Zou
    Gregory J. Tracey
    Nature Communications, 14
  • [22] A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
    Chen, Li
    Zhang, Jiayi
    Sun, Yu
    Zhao, Yu
    Liu, Xiang
    Fang, Zhiyin
    Feng, Lingge
    He, Bin
    Zou, Quanfei
    Tracey, Gregory J.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [23] Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine
    Blumenfeld, Andrew M.
    Boinpally, Ramesh
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    Dabruzzo, Brett
    Ailani, Jessica
    Lipton, Richard B.
    HEADACHE, 2023, 63 (03): : 322 - 332
  • [24] Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants
    Zhang, Ying
    Johnson, Mark
    Joshi, Samit
    Yazdani, Parto
    Zhan, Joyce
    Wen, Bo
    Bainbridge, Veronica
    Gartland, Martin
    Lataillade, Max
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (07) : 2236 - 2245
  • [25] A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
    Morrison, Gilmour
    Crockett, Julie
    Blakey, Graham
    Sommerville, Kenneth
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (08): : 1009 - 1031
  • [26] AN OPEN-LABEL, PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS (PK) AND DRUG-DRUG INTERACTIONS OF SETANAXIB TABLETS IN HEALTHY ADULTS
    Szyndralewiez, Cedric
    Laurijssens, Bart
    Carlsson, Stefan
    Philipson, Richard
    HEPATOLOGY, 2022, 76 : S1468 - S1468
  • [27] DRUG INTERACTION STUDY OF APIXABAN WITH CYCLOSPORINE AND TACROLIMUS: RESULTS FROM A PHASE I, OPEN-LABEL, CROSSOVER TRIAL IN HEALTHY VOLUNTEERS.
    Bashir, B.
    Tran, B. D.
    Mantravadi, S.
    Stickle, D. F.
    Chervoneva, I.
    Kraft, W. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S25 - S25
  • [28] Impact on Abiraterone Pharmacokinetics and Safety: Open-Label Drug-Drug Interaction Studies with Ketoconazole and Rifampicin
    Bernard, Apexa
    Vaccaro, Nicole
    Acharya, Milin
    Jiao, James
    Monbaliu, Johan
    De Vries, Ronald
    Stieltjes, Hans
    Yu, Margaret
    Tran, Namphuong
    Chien, Caly
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (01): : 63 - 73
  • [29] Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial
    Boinpally, Ramesh
    Jakate, Abhijeet
    Butler, Matthew
    Periclou, Antonia
    PAIN MANAGEMENT, 2021, 12 (04) : 499 - 508
  • [30] Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study
    Dow, James
    Currie, Alexander
    He, Ling
    Zaidi, Faisal
    Zahir, Hamim
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (10) : 451 - 458
12345